Targeted Genetics Corp., of Seattle, completed acquisition of Biocontrol Ltd., of London. Targeted Genetics will issue 22,586,073 shares of common stock to Biocontrol shareholders, who will then hold about 50 percent of Targeted Genetics. As a condition prior to the acquisition, Biocontrol raised $310,000 in working capital for use by Targeted Genetics.